Next-Generation Manufactured Red Blood Cells for Extended Battlefield Blood Supply: Safi Biotherapeutics

The Problem: Uncontrolled hemorrhage remains one of the leading causes of preventable death on the battlefield, historically accounting for approximately 90% of preventable combat fatalities. Delivering life-saving blood transfusions at or near the point of injury is often constrained by the limited shelf life of donor red blood cells (dRBCs) and the logistical burden of maintaining a reliable cold chain supply across global military operations. Aligning supply with unpredictable demand presents a persistent challenge for the Armed Services Blood Program network, particularly in austere or remote environments. Extended shelf-life blood products that can supplement existing inventories are therefore a strategic priority for military medicine. Without reliable access to stable, readily available blood products, warfighters face an increased risk of death from hemorrhage, delayed recovery, and reduced survivability during prolonged field care operations.

Solution & Progress: Safi Biotherapeutics is a preclinical blood cell therapy company pioneering industrial-scale manufacturing of adult stem-cell–derived human red blood cells (mRBCs) designed to augment the existing blood supply for both military and civilian transfusion needs. Safi’s mRBC product is being developed as a readily available universal donor–typed blood product that is free of immune cells and pathogens, offering the potential for increased shelf life and improved clinical outcomes. As a homogeneous population of newly generated red blood cells with a near-full lifespan, Safi mRBCs may improve circulation time and support faster recovery compared with conventionally stored donor blood. The company is advancing both cryopreserved formulations for long-term hospital storage and shelf-stable, freeze-dried formats intended for far-forward military and civilian pre-hospital environments, including EMS and MEDEVAC operations.

Since receiving its MTEC award, Safi has achieved several major milestones, including the successful technical transfer of its clinical-scale (10-liter bioreactor) mRBC production system to a U.S.-based CDMO in a pre-GMP environment and the completion of pre-clinical animal studies demonstrating a circulatory half-life equivalent to dRBCs. Additional studies confirmed enhanced oxidative resilience and improved recovery following cryopreservation and freeze-drying using tailored storage strategies. Safi has also demonstrated consistent functional performance across mRBC units, including extended circulation time and potentially reduced first-pass clearance. These advances have accelerated Safi’s regulatory pathway, positioning the company for a pre-IND meeting by mid-2026, followed by IND submission and first-in-human clinical trials planned for 2027.

Impact & the Role of MTEC: If successful, Safi’s mRBCs will significantly enhance military readiness by providing a reliable, scalable, and extended shelf-life blood supply capable of supporting trauma care in both deployed and civilian environments. The ability to store cryopreserved or freeze-dried mRBC products for extended periods will improve casualty stabilization during the critical early phases of care, strengthen medical logistics flexibility, and reduce reliance on traditional donor blood supply chains. These capabilities have the potential to improve warfighter survivability, enable more effective prolonged field care, and support large-scale emergency preparedness across military and government healthcare systems.

MTEC and its Government sponsor have played a central role in advancing this effort through Award 24-01-MPAI, “Optimization and Standardization of Enhanced Cryo-Storage Capabilities Unique to Manufactured Red Blood Cells (mRBCs).” This support has enabled refinement of cryopreservation methods demonstrating improved resistance of mRBCs to storage-related stress, development of glycerol- and DMSO-free freezing strategies, and optimization of cell specifications to maximize long-term storage viability and transport readiness. The award has also supported refinement of FDA-recommended animal models and development of clinical strategies for acute blood loss indications relevant to military trauma and emergency response applications.

For more information on Safi, visit https://safi.bio/ and linkedin.com/company/safi-biosolutions-inc/